Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows

Inclusion Criteria: 1. 18 to 80 years of age; 2. Acute ischemic stroke with National Institute of Health Stroke Scale (NIHSS) ≥ 10 and Volume of infarction on DWI \<31ml or with a NIHSS ≥20 and 31ml\<Volume of infarction\<51ml(DWI); 3. Patients who presented with acute ischemic stroke and a large vessel occlusion in the anterior circulation; 4. Endovascular Therapy in 6-24 hours of stroke onset; 5. The availability of informed consent. Exclusion Criteria: 1. First ever stroke or mRS≤1 after previous disease; 2. Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage; 3. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia 4. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis; 5. Severe cardiac or pulmonary disease; 6. Patients with malignant tumor or under antineoplastic therapy with estimated lifetime less than 3 months; 7. Pregnancy, plan to get pregnant or during lactation; 8. Patients with contraindication or allergic to any ingredient of drugs in our study; 9. Unsuitable for this clinical studies assessed by researcher